Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019
Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019
Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019
- 25 June 2019 - 0 mins read
Related Press Releases
23 October 2024
4 mins read
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
14 October 2024
5 mins read
Ipsen receives its second Shingo Prize for operational excellence
23 September 2024
8 mins read
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
20 September 2024
8 mins read
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
16 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
15 September 2024
7 mins read
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
26 July 2024
12 mins read
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
25 July 2024
7 mins read
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
25 July 2024
11 mins read
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
11 July 2024
6 mins read